Advertisement

The Development of New Antileukotriene Drugs: Specific Leukotriene D4 Antagonists and 5-Lipoxygenase Inhibitors

  • Joshua Rokach
  • Robert N. Young
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 259)

Abstract

The leukotrienes are a complex set of metabolites derived from oxidative metabolism of arachidonic acid (1). The release of arachidonic acid from phospholipid stores by specific phospholipases, when accompanied by a specific activation of an enzyme known as 5-lipoxygenase, results in the conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) (2). Through a specific dehydration step, this same enzyme can convert 5-HPETE to the reactive epoxide known as leukotriene A4 (LTA4) (3) . LTA4 can be hydrated by a specific LTA4 hydrolase enzyme which introduces a hydroxyl group in the 12R position to produce leukotriene B4 (LTB4, 5[S], 12[R]-dihydroxy-6, 14[Z]-8, 10[E]-eicosatetraenoic acid) (4). LTBa is a potent stimulator of leukocyte migration in vitro (1–3) and in vivo (4) and is comparably potent with chemotactic factors such as C5A and the synthetic peptide f-Met-Leu-Phe. In addition, LTB4 causes aggregation of polymorphonuclear leukocytes (PMNs) and exudation of plasma and has been shown to stimulate phospholipase A2. LTB4 has also been shown to contract human bronchus and guinea pig lung strips. The potent biological effects of LTBa and the demonstrated measurable levels of LTB4 in psoriatic tissue (5) have led to the speculation that LTB4 may play an important role in mediating inflammatory responses in man.

Keywords

Dynamic Compliance Allergic Conjunctivitis Insufflation Pressure Schild Analysis Human Glomerular Epithelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A.W. Ford-Hutchinson, M.A. Bray, M.V. Doig, M.E. Shipley, M.J.H. Smith, Leukotriene B: a potent chemokinetic and aggregating substance released from polymorphonuclear leucocytes, Nature 286:264–265 (1980).PubMedCrossRefGoogle Scholar
  2. 2.
    M.H.J. Smith, A.W. Ford-Hutchinson, M.A. Bray, Leukotriene B: a potential mediator of inflammation, J. Pharm. Pharmacol. 32:517–518 (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    E.J. Goetzl and W.C. Pickett, The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs), J . Immunol. 125:1789–1791 (1980).PubMedGoogle Scholar
  4. 4.
    M.A. Bray, F.M. Cunningham, A.W. Ford-Hutchinson, M.J.H. Smith, Leukotriene B4: an inflammatory mediator in vivo, Br. J. Pharmacol. 22:483–486 (1981).CrossRefGoogle Scholar
  5. 5.
    S.D. Brain, R.D.R. Camp, R.M. Dowd, A. Kobza-Black, P.M. Wollard, A.I. Mallet, M.W. Greaves, Psoriasis and leukotrienes B4, Lancet ii:762 (1982).CrossRefGoogle Scholar
  6. 6.
    B. Samuelsson, Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation, Science (Washington, D.C.) 220:568–575 (1983).PubMedCrossRefGoogle Scholar
  7. 7.
    J. Verhagen, P.L.B. Braynzee, J.A. Koedam, G.A. Wassink, M. Boer, G.K. Terpstra, J. Kreukniet, G.A. Veldink, J.F.G. Vliegenthart, Specific leukotriene formation by purified human eosinophils and neutrophils, FEBS Letters. 168:23–28 (1984).PubMedCrossRefGoogle Scholar
  8. 8.
    M. Damon, C. Chavis, P. Goodard, F.B. Michel, A. Crastes de Paulet, Purification and mass spectrometry identification of leukotriene D4 synthesized by human alveolar macrophages, Biochem. Biophys. Res. Commun. 111:518–524 (1983).PubMedCrossRefGoogle Scholar
  9. 9.
    D.W. MacGlashan Jr., R.P. Schleimer, S.P. Peters, E.S. Schulman, G.K. Adams III, H.H. Newball, Generation of leukotrienes by purified human lung mast cells, J. Clin. Invest. 70:747–751 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    S.E. Dahlen, P. Hedqvist, S. Hammarstrom, B. Samuelsson, Leukotrienes are potent constrictors of human bronchi, Nature (London) 288:484–486 (1980).CrossRefGoogle Scholar
  11. 11.
    J.M. Drazen, K.F. Austen, R.A. Lewis, D.A. Clark, G. Goto, A. Marfat, E.J. Corey, Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro, Proc. Nat’l. Acad. Sci. USA 77:4354–4358 (1980).CrossRefGoogle Scholar
  12. 12.
    C.J. Hanna, M.K. Bach, P.D. Pare, R.R. Schellenberg, Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro, Nature (London) 290:343–344 (1981).CrossRefGoogle Scholar
  13. 13.
    P.J. Piper, M.N. Samhoun, J.R. Tippins, T.J. Williams, M.A. Plamer, M.J. Peck, Pharmacological studies on pure SRS-A and synthetic leukotrienes C4 and D4. In: “SRS-A and leukotrienes,” P.J. Piper, ed., Wiley, Chichester, England, pp. 81–99 (1981).Google Scholar
  14. 14.
    T.R. Jones, C. Davis, E.E. Daniel, Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle, Can. J. Physiol. Pharmacol. 60:638–643 (1982).PubMedCrossRefGoogle Scholar
  15. 15.
    H. Bisgaard and M. Pederson, SRS-A dampens the activity of human cilia, Fed. Proc. 42:1381 (1983).Google Scholar
  16. 16.
    J.D. Lundgren, J.H. Shelhamer, M.A. Kaliner, The role of eicosanoids in respiratory mucus hypersecretion, Ann. Allergy 55:5–8 (1985).PubMedGoogle Scholar
  17. 17.
    C.L. Malmsten and I.M. Goldstein, Leukotrienes: mediators of inflammatory and immediate hypersensitivity reactions, CRC Crit. Rev. Immunol. 4:307–333 (1984).Google Scholar
  18. 18.
    J.W. Weiss, J.M. Drazen, N. Coles, E.R. McFadden Jr., P.F. Weller, E.J. Corey, R.A. Lewis, K.F. Austen, Bronchoconstrietor effects of leukotriene C in humans, Science (Washington, D.C.) 216:196–198 (1982).CrossRefGoogle Scholar
  19. 19.
    M. Griffin, J.W. Weiss, A.G. Leitch, E.R. McFadden Jr., E.J. Corey, K.F. Austen, J.M. Drazen, Effects of leukotriene D on the airways in asthma, N. Engl. J. Med. 308:436–439 (1983).PubMedCrossRefGoogle Scholar
  20. 20.
    J.C. Delehunt, A.P. Perruchoud, L. Yerger, B. Marchette, J.S. Stevenson, W.M. Abraham, The role of slow-reacting substance of anaphylaxis in the late bronchial response after antigen challenge in allergic sheep, Am. Rev. Respir. Dis. 130:748–754 (1984).PubMedGoogle Scholar
  21. 21.
    W.M. Abraham, E. Russi, A. Wanner, J.C. Delehunt, L.D. Yerger, G.A. Chapman, Production of early and late pulmonary responses with inhaled leukotriene D4 in allergic sheep, Prostaglandins 29:715–726 (1985).PubMedCrossRefGoogle Scholar
  22. 22.
    E. Pirotzky, J. Bidault, C. Burtin, M.C. Gubler, J. Benveniste, Release of platelet activating factor, slow-reacting substance and vasoactive amines from isolated rat kidney, Kidney Int. 25:404–410 (1984).PubMedCrossRefGoogle Scholar
  23. 23.
    E.S.K. Assem and N. Azizan Abdullah, Release of thromboxane B2 and leukotriene C4 and reduction in renal perfusion in experimental anaphylactic reaction of isolated guinea pig kidney, Int. Archs. Allergy Appl. Immun. 82:212–214 (1987).CrossRefGoogle Scholar
  24. 24.
    J. Sraer, M. Bens, R. Ardaillou, J.D. Sraer, Sulfidopeptide leukotriene biosynthesis and metabolism by rat glomeruli and papilla (abstr.), Kidney Int. 29:346 (1986).Google Scholar
  25. 25.
    E.A. Lianos, Glomerular leukotriene biosynthesis and degradation in the rat: effects of immune injury (abstr.), Kidney Int. 29:339 (1986).Google Scholar
  26. 26.
    V. Cattell, J. Smith, H.T. Cook, S. Moneada, J.A. Salmon, Leukotriene B4 synthesis in normal rat glomeruli (abstr.), Kidney Int. 27:254 (1985).Google Scholar
  27. 27.
    M.A. Rahman, M. Nakazawa, S.N. Emancipator, M.J. Dunn, Increased leukotriene B4 (LTB4) synthesis in immune-injured rat glomeruli (abstr.), Kidney Int. 29:343 (1986).Google Scholar
  28. 28.
    R. Barnett, P. Goldwasser, L.A. Scharschmidt, D. Schlondorff, Effects of leukotrienes on isolated rat glomeruli and cultured mesangial cells, Am. J. Phvsiol. 250:F838–F844 (1986).Google Scholar
  29. 29.
    M. Simonson and M.J. Dunn, Leukotriene C4 and D4 contract rat glomerular mesangial cells, Kidney Int. 30:524–531 (1986).PubMedCrossRefGoogle Scholar
  30. 30.
    L. Baud, J. Sraer, J. Perez, M.P. Nivez, R. Ardaillou, Leukotriene C4 binds to human glomerular epithelial cells and promotes their proliferation in vitro, J. Clin. Invest. 76:374–377 (1985).PubMedCrossRefGoogle Scholar
  31. 31.
    A. Rosenthal and C.R. Pace-Asciak, Potent vasoconstriction of the isolated perfused rat kidney by leukotrienes C4 and D4, Can. J. Phvsiol. Pharmacol. 61:325–328 (1983).CrossRefGoogle Scholar
  32. 32.
    P.J. Piper, A.W.B. Stanton, L.J. McLeod, The actions of leukotrienes C4 and D4 in the porcine renal vascular bed, Prostaglandins 29: 61–73 (1985).PubMedCrossRefGoogle Scholar
  33. 33.
    K.F. Badr, C. Baylis, J.M. Pfeffer, M.A. Pfeffer, R.J. Soberman, R.B. Lewis, K.F. Austen, E.J. Corey, Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat, Circ. Res. 54:492–499 (1984).PubMedCrossRefGoogle Scholar
  34. 34.
    K.F. Badr, B.M. Brenner, M. Wasserman, I. Ichikawa, Evidence for local glomerular actions of leukotriene D4 (abstr.), Kidney Int. 29:328 (1986).Google Scholar
  35. 35.
    K.F. Badr, B.M. Brenner, I. Ichikawa, Effects of leukotriene D4 on glomerular dynamics in the rat, Am. J. Physiol. 22:F239–F243 (1987).Google Scholar
  36. 36.
    K.F. Badr, A. Gung, G.F. Schreiner, M. Wasserman, I. Ichikawa, Reversal of antiglomerular basement membrane antibody-induced fall in the glomerular ultrafiltration coefficient by the leukotriene D4 antagonist SK&F 10453 (abstr.), Kidney Int. 31:363, 1987.Google Scholar
  37. 37.
    R. Ardaillou, L. Baud, J. Sraer, Leukotrienes and other lipoxygenase products of arachidonic acid synthesized in the kidney, Am. J. Med. 81(suppl. B):12–22 (1986).PubMedCrossRefGoogle Scholar
  38. 38.
    D.W. Snyder and R.D. Krell, Pharmacological evidence for a distinct leukotriene C4 receptor in guinea pig trachea, J. Pharmacol. Exp. Ther. 231:616–622 (1984).PubMedGoogle Scholar
  39. 39.
    S.S. Pong and R.N. DeHaven, Characterization of a leukotriene D4 receptor in guinea pig lung, Proc. Natl. Acad. Sci. USA 80:7415–7419 (1983).PubMedCrossRefGoogle Scholar
  40. 40.
    S.S. Pong, R.N. DeHaven, F.A. Keuhl Jr., R.W. Egan, Leukotriene C4 binding to rat lung membranes, J. Biol. Chem. 258:9615–9619 (1983).Google Scholar
  41. 41.
    G.K. Hogaboom, M.S. Mong, H. Wu, S.T. Crooke, Peptido-leukotrienes : distinct receptors for leukotriene C4 and D4 in the guinea pig lung, Biochem. Biophvs. Res. Commun. 116:1136–1143 (1983).CrossRefGoogle Scholar
  42. 42.
    S. Mong, H.L. Wu, M.O. Scott, M.A. Lewis, M.A. Clark, B.M. Weichman, C.M. Kinzig, J.G. Gleason, S.T. Crook, Molecular heterogeneity of leukotriene receptors : correlation of smooth muscle contraction and radioligand binding in guinea-pig lung, J. Pharmacol. Exp. Ther. 234:316–325 (1985).PubMedGoogle Scholar
  43. 43.
    B.J. Ballerman, R.A. Lewis, E.J. Corey, K.F. Austen, B.M. Brenner, Identification and characterization of leukotriene C4 receptors in isolated rat renal glomeruli, Circ. Res. 56:324–330 (1985).CrossRefGoogle Scholar
  44. 44.
    C.K. Buckner, R.D. Krell, R.B. Laravusa, D.B. Coursin, P.R. Bernstein, J.N. Will, Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4, J. Pharmac. Exp. Ther. 237:558–562 (1986).Google Scholar
  45. 45.
    T. Ahmed, D.W. Greenblatt, S. Birch, B. Marchette, A. Wanner, Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: role of slow-reacting substance of anaphylaxis, American Review of Respiratory Disease 124:110 (1981).PubMedGoogle Scholar
  46. 46.
    M.C. Holroyde, R.E.C. Altounyan, M. Cole, M. Dixon, E.V. Elliott, Bronchoconstriction produced in man by leukotrienes C and D, Lancet 11:17 (1981).CrossRefGoogle Scholar
  47. 47.
    R.E.C. Altounyan and M. Cole, Therapeutic implications: “Proceedings of the Xth International Congress of Allergology and Clinical Immunology,” J.W. Kerr, ed., Macmillan, London, p. 271 (1983).Google Scholar
  48. 48.
    T.H. Lee, M.J. Walport, A.H. Wilkinson, M. Turner-Warwick, A.B. Kay, Slow-reacting substance of anaphylaxis antagonist FPL-55712 in chronic asthma, Lancet ii:304 (1981).CrossRefGoogle Scholar
  49. 49.
    W.S. Marshall, T. Goodson, G.J. Cullinan, D. Swanson-Bean, K.D. Haish, L.E. Rinkema, J.H. Fleish, Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives, J. Med. Chem. 30:682–689 (1987).PubMedCrossRefGoogle Scholar
  50. 50.
    M. Cloud, G. Eras, J. Kemp, T. Platts-Mills, L. Altnan, R. Townley, D. Tinkelman, T. King, E. Middleton, A. Sheffer, E. McFadden, Efficacy and safety of LY171883 in patients with mild chronic asthma, J. Allergy. Clin. Invest. (abstr.) 79:525 (1987).Google Scholar
  51. 51.
    J.H. Fleish, L.E. Rinkema, K.D. Haisch, D. McCullough, F.P. Carr, R.D. Dillard, Evaluation of LY163443, 1-[2-hydroxy-3-propyl-4-{[4-(1H-tetrazol-5-ylmethyl)phenoxy]methyl}phenyl] ethanone, as á pharmacological antagonist of leukotriene D4 and E4. Naunyn-Schmiedeberg’s Arch. Pharmacol. 333:70–77 (1986).CrossRefGoogle Scholar
  52. 52.
    J.G. Gleason, R.F. Hall, C.D. Perchonock, K.F. Erhard, J.S. Frazee, T.V. Ku, K. Kondrad, M.E. McCartney, S. Mong, S.T. Crooke, G. Chi-Rosso, M.A. Wasserman, T.J. Torphy, R.M. Muceitelli, D.W. Hay, S.S. Tucker, L. Vickery-Clark, High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3[(2-carboxy-ethyl) thio] -3- [2- (8-phenylocyl)phenyl]propanoic acid, J. Med. Chem. 30:959–961 (1987).PubMedCrossRefGoogle Scholar
  53. 53.
    R.G. Van Inwegen, A. Khandwala, R. Gordon, P. Sonnino, S. Coutts, S. Jolly, REV5901: an orally effective peplidoleukotriene antagonist, detailed biochemical/pharmacological profile, J. Pharmacol. Exp. Ther. 241:117–123 (1987).PubMedGoogle Scholar
  54. 54.
    J.M. Hand, L.M. Marshall, J.H. Musser, A.F. Kreft, L. Marinari, S. Schwalm, I. Englebach, A. Auen, J. Chang, The pharmacology of WY-48, 252: a novel selective and orally active antagonist of leukotriene D4 (abstr.), Conference on the Biology of the Leukotrienes, (N.Y. Acad. Sci.), Philadelphia, June 28-July 1 (1987).Google Scholar
  55. 55.
    N.C. Barnes, The actions of leukotriene agonists, antagonists and synthesis inhibitors in man (abstr.), Xth Int. Congress Pharmacol., Sydney, Australia, Aug. 23–28 (1987).Google Scholar
  56. 56.
    P.R. Bernstein, Y.K. Yee, D. Snyder, A novel class of peptidoleukotriene antagonists: the bioisosterism of ketosulfone derivatives and acylsul-fonamides (abstr.), 194th ACS National Meeting, New Orleans, August 30-September 4, (1987).Google Scholar
  57. 57.
    A. Lassus and S. Forsstrom, A dimethoxynaphthalene derivative RS-43179 gel compared with 0.025 percent fluocinoline acetonide gel in the treatment of psoriasis, Br. J. Dermatol. 113:103–106 (1985).PubMedCrossRefGoogle Scholar
  58. 58.
    K. Miyasaka, T. Mikami, K. Miyazawa, M. Hagiwara, Inhibitory effect of 2-phenylindole derivative TZ1–44127 of 5-lipoxygenase, Jpn. J. Pharmacol. 43(supp1.):118 (1987).Google Scholar
  59. 59.
    M. Fujimura, F. Sasaki, Y. Nakatsumi, Y. Takahashi, S. Hifumi, K. Taga, J. Mifune, T. Tanaka, T. Matsuda, Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects, Thorax 41:955–959 (1986).PubMedCrossRefGoogle Scholar
  60. 60.
    A.W. Ford-Hutchinson, G. Brunet, R. Hamel, H. Piechuta, G. Holme, Respiratory responses to leukotriene and biogenic amines in normal and hyperreactive rats, J. Immunol. 131:434–438 (1983).PubMedGoogle Scholar
  61. 61.
    C.S. McFarlane, H. Piechuta, R.A. Hall, A.W. Ford-Hutchinson, Effects of a contractile prostaglandin antagonist (L-640, 035) upon allergen-induced bronchoconstriction in hyperreactive rats and conscious squirrel monkeys, Prostaglandins 28:173–182 (1984).PubMedCrossRefGoogle Scholar
  62. 62.
    J.G. Atkinson and J. Rokach, Synthesis of leukotrienes, In: “Handbook of Eicosanoids,” Vol. 1, Part B, A.L. Willis, ed., C.R.C. Press, Boca Raton, Florida (1987).Google Scholar
  63. 63.
    E.J. Corey, D.A. Clark, A. Marfat, In: “The Leukotrienes Chemistry and Biology,” L.W. Chakrin and D.M. Bailey, eds., pp. 14–103, Academic Press, London (1984).Google Scholar
  64. 64.
    J. Augstein, J.B. Farmer, T.B. Lee, P. Sheard, M.L. Tattersall, Selective inhibitor of slow-reacting substance and anaphylaxis, Nature New Biol. 245:215 (1973).PubMedCrossRefGoogle Scholar
  65. 65.
    R.N. Young, P. Belanger, E. Champion, R.N. DeHaven, D. Denis, A.W. Ford-Hutchinson, R. Fortin, R. Frenette, J-Y. Gauthier, J. Gillard, Y. Guindon, T.R. Jones, M. Kakushima, P. Masson, A. Maycock, C.S. McFarlane, H. Piechuta, S.S. Pong, J. Rokach, H. Williams, C. Yoakim, R. Zamboni, Design and synthesis of sodium (ß&, γS*)-4-{[3-(4-acetyl- 3-hydroxy-2-propyl]thio}-γ -hydroxy-β-methylbenzene-butanoate: a novel, selective and orally-active receptor antagonist of leukotriene D4, J. Med. Chem. 29:1573–1576 (1986).PubMedCrossRefGoogle Scholar
  66. 66.
    T.R. Jones, R. Young, E. Champion, L. Charette, R.N. DeHaven, D. Denis, A.W. Ford-Hutchinson, R. Frenette, J-Y. Gautheri, Y. Guindon, M. Kakushima, P. Masson, A. Maycock, S.S. Pong, J. Rokach, R. Zamboni, L-649, 923, sodium (ßS*, γR*) -4- (3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)propylthio)- -hydroxy-ß-methylbenzenebutanoate. A selective, orally active leukotriene receptor antagonist, Can. J. Phvsiol. Pharmacol. 64:1068–1075 (1986).CrossRefGoogle Scholar
  67. 67.
    D. Arunlakshana and H.O. Schild, Some quantitative uses of drug antagonists, Br. J. Pharmacol. 14:48–58 (1959).Google Scholar
  68. 68.
    T.R. Jones and P. Masson, Comparative study of the pulmonary effects of intravenous leukotrienes and other bronchoconstrictors in anesthetized guinea-pigs, Prostaglandins 29:799–817 (1985).PubMedCrossRefGoogle Scholar
  69. 69.
    J.H. Fleisch, L.E. Rinkema, K.D. Haisch, D. Swanson-Bean, T. Goodson, P.P.K. Ho, W.S. Marshall, LY-171883, 1-(2-hydroxy-3-propyl-4-(4-(1H-tetrazol-5-yl)butoxy)-phenyl)-ethanone, an orally active leukotriene D4 antagonist, J. Pharmacol. Exp. Ther. 233:148–157 (1985).PubMedGoogle Scholar
  70. 70.
    T.R. Jones, Y. Guindon, R.N. Young, E. Champsion, L. Charette, D. Denis, D. Ethier, R. Hamel, A.W. Ford-Hutchinson, R. Fortin, G. Letts, P. Masson, C. McFarlane, H. Piechuta, J. Rokach, C. Yoakim, R.N. DeHaven, A. Maycock, S.S. Pong, L-648, 051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylsulfonyl]-γ-oxo-benze nebutanoate: a leukotriene D4 receptor antagonist, Can. J. Physiol. Pharmacol. 64:1535–1542 (1986).PubMedCrossRefGoogle Scholar
  71. 71.
    N. Barnes, P.J. Piper, J. Costello, The effect of an oral leukotriene antagonist L-649–923 on histamine and leukotriene D4-induced bronchoconstriction in normal man, J. Allergy Clin. Immunol. 79:816–821 (1987).PubMedCrossRefGoogle Scholar
  72. 72.
    N.C. Barnes, J. Evans, J.T. Zakrzewski, P.J. Piper, F. Costello, L-648,051 A leukotriene D4 antagonist is active by the inhaled route in man (abstr.), Xth Int. Congress Pharmacol., Sydney, Australia, August 23–28 (1987).Google Scholar
  73. 73.
    Y. Guindon, Y. Girard, A. Maycock, A.W. Ford-Hutchinson, J.G. Atkinson, P.C. Belanger, A. Dallob, D. DeSousa, H. Dougherty, R. Egan, M.M. Goldenberg, E. Ham, R. Fortin, P. Hamel, R. Hamel, C.K. Lau, Y. Leblanc, C.S. McFarlane, H. Piechuta, M. Thérien, C. Yoakim, and J. Rokach, L-651, 392: a novel, potent and selective 5-lipoxygenase inhibitor, In: “Advances in Prostaglandin, Thromboxane and Leukotriene Research,” Vol. 17A, B. Samuelsson, R. Paoletti and P.W. Pamwell, eds., Raven Press, New York (1986).Google Scholar
  74. 74.
    H. Piechuta, A.W. Ford-Hutchinson, G.L. Letts, Inhibition of allergeninduced bronchoconstriction in hyperreactive rats as a model for testing 5-lipoxygenase inhibitors and leukotriene D4 antagonists, Agents and Actions, in press.Google Scholar
  75. 75.
    C.S. McFarlane, R. Hamel, A.W. Ford-Hutchinson, Effects of a 5-lipoxygenase inhibitor (L-651, 392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey, Agents and Actions. in press.Google Scholar
  76. 76.
    D. Garceau, A.W. Ford-Hutchinson, S. Charleson, 5-lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea pig, Europ. J . Pharmacol.. in press.Google Scholar
  77. 77.
    C-C. Chan, L. Dubois, V. Young, Effects of two novel inhibitors of 5-lipoxygenase, L-651, 392 and L-651, 896, in a guinea-pig model of epidermal hyperproliferation, Europ. J. Pharmacol. 139:11–18 (1987).CrossRefGoogle Scholar
  78. 78.
    J.W. Coggeshall, W.E. Serofin, M.A. Philips, P.L. Lefferts, J.R. Snapper, Role of leukotrienes in an animal model of the adult respiratory distress syndrome, Am. Rev. Respir. Dis., in press.Google Scholar
  79. 79.
    A. Yared, A. Gung, G. Schreiner, I. Ichikawa, K.F. Badr, Leukotriene D4 (LTD4)-induced protein urea: role in experimental glomerulonephritis (abstr.), Xth International Congress of Nephrology, London (1987).Google Scholar
  80. 80.
    J.T. Beck, A.J. Boyd, P.K. Dinda, Evidence for the involvement of 5-lipoxygenase products in the ethanol-induced intestinal plasma protein loss, submitted for publication.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Joshua Rokach
    • 1
  • Robert N. Young
    • 1
  1. 1.Merck Frosst Canada, Inc.QuebecCanada

Personalised recommendations